Items Tagged with 'Alzheimerâs disease'
On January 17, 2012, Medivation, Inc.(NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer’s disease.
Your Financial Security is Serious Business...
so why should you trust The Turnaround Letter?
Ranked Among Top-2 for 15-Yr. Returns: Turnaround Letter's 12.1% vs. S&P's 2.5%
28+ Years of Turnaround Investing Experience & Reliable Stock Market Advice
Diverse Monthly Stock Picks Personally Selected by George Putnam
Distressed Investing Blog
Most investors remember the severity of the 2009 market nosedive: The Dow's final closing price on March 9, 2009 was just 6,547.05, and the S&P 500 dropped to just 676.53. Looking back now with six years of hindsight under our belt, we recently took a look at some of the stocks that have significantly lagged over the six-year period since the March 9, 2009 low point for some unique value stock opportunities.
George Putnam has always followed the same straight-forward and highly-profitable investment philosophy. He published his first Turnaround Letter issue back in 1986, and readers have seen extraordinary long-term stock profit ever since.
In fact, 12 of 2014's 13 closed-out purchase recommendations saw gains--with five of those enjoying total returns greater than 100%. The Turnaround Letter's average return for 2014's stock picks is +82%:
2014 Closed Out Purchase Recommendations
* Calculation includes dividends and price changes between purchase recommendation and current price.
Copyright © All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing.